Blood test to predict immunotherapy benefit in advanced cancer
Treatments studied
Part of Cancer, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial is testing a simple blood test to see if it can predict how well immunotherapy will work for people with advanced cancer. It's for those newly diagnosed with certain cancers and about to start immunotherapy as their first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic cancer that has spread (stage 3 or 4).
- You have one of these cancer types: non-small cell lung cancer, melanoma, head and neck cancer, kidney cancer, or triple-negative breast cancer.
- You are about to start immunotherapy (like Keytruda, Opdivo, or Tecentriq) as your first treatment, alone or with chemotherapy or other drugs.
- You are in good enough health to be up and about (ECOG performance status 0-2).
- Your blood counts and kidney/liver function are within normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a simple blood test can predict how well your immune system will respond to immunotherapy (such as Keytruda or Opdivo). You may qualify if you have lung cancer (NSCLC) or advanced melanoma and are about to start this type of treatment for the first time.
This trial is for people with advanced non-small cell lung cancer (NSCLC) who have not yet started treatment. It studies a simple blood test that checks for genetic changes in the cancer, to help doctors choose the most effective first treatment.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This trial is looking at a blood test to predict how well combined immunotherapy and chemotherapy will work in people with advanced lung cancer. It uses a new marker called ETASTs to help guide treatment decisions.
This trial tests whether a “liquid biopsy” blood test can help predict how well first immunotherapy will work for people with stage IV lung cancer. It may help doctors choose the most effective treatment strategy sooner.
This Phase 2 study tests how results from blood cancer DNA tests (ctDNA) can help choose the best immune therapy approach for newly diagnosed, advanced lung cancer. It aims to improve outcomes by matching treatment decisions to a patient’s immune and blood test “profile.”
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.